FibroGen (NASDAQ:FGEN) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

FibroGen (NASDAQ:FGEN) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09, Zacks reports. The company had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter in the prior year, the business earned ($0.65) EPS.

FibroGen Stock Performance

FGEN stock traded up $0.02 during mid-day trading on Wednesday, hitting $0.46. The company had a trading volume of 2,546,140 shares, compared to its average volume of 2,680,453. The firm has a market cap of $45.76 million, a PE ratio of -0.18 and a beta of 0.71. FibroGen has a 12 month low of $0.33 and a 12 month high of $2.93. The stock’s fifty day moving average price is $1.00 and its two-hundred day moving average price is $1.43.

Wall Street Analyst Weigh In

Separately, William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Monday, June 3rd.

Insider Activity

In other news, insider Deyaa Adib bought 22,123 shares of the stock in a transaction on Wednesday, June 12th. The shares were purchased at an average cost of $1.17 per share, for a total transaction of $25,883.91. Following the completion of the purchase, the insider now directly owns 82,123 shares in the company, valued at approximately $96,083.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.98% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.